Skip to main content
Premium Trial:

Request an Annual Quote

Dako to Develop Cancer Companion Dx for Bristol-Myers Squibb

NEW YORK (GenomeWeb News) – Dako said today that it will collaborate with drug maker Bristol-Myers Squibb to develop clinical diagnostics as companions to cancer therapeutics.
 
The Danish diagnostics firm plans to develop clinical diagnostics that can identify cancer patients who may benefit from drug candidates that Bristol-Myers Squibb has in development.
 
Dako CEO Patrick Dahlen said the tests it develops under the collaboration will be companion products for specific Bristol-Myers Squibb therapeutics.
 
Further terms of the agreement were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.